Table 1

Main baseline demographic and clinical characteristics of patients with active AS (n=20) treated with ustekinumab in the TOPAS trial

ParameterValue
Age, years (mean±SD)37.5±10.8
Duration of symptoms, years (mean±SD)13.3±10.5
Male gender, n (%)15 (75)
HLA-B27 (+), n (%)18 (90)
Peripheral arthritis, n (%)1 (5)
Enthesitis, n (%)8 (40)
Uveitis ever, n (%)3 (15)
Psoriasis ever, n (%)1 (5)
IBD ever, n (%)1 (5)
Elevated (>5 mg/l) CRP, n (%)8 (40)
Concomitant treatment with NSAIDs, n (%)17 (85)
Concomitant treatment with DMARDs, n (%)0 (0)
Concomitant treatment with systemic steroids, n (%)1 (5)
Past treatment with a TNFα blocker, n (%)1 (5)
  • AS, ankylosing spondylitis; CRP, C reactive protein; DMARDs, disease-modifying antirheumatic drugs ; HLA, human leukocyte antigen; IBD, inflammatory bowel disease; NSAIDs, non-steroidal anti-inflammatory drugs; TNFα, tumour necrosis factor α.